Epileptic Encephalopathy, Early Infantile, 2 disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

EIEE2 MCID: EPL025 MIFTS: 45	Epileptic Encephalopathy, Early Infantile, 2 (EIEE2) Categories: Eye diseases, Fetal diseases, Genetic diseases, Liver diseases, Mental diseases, Metabolic diseases, Neuronal diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Epileptic Encephalopathy, Early Infantile, 2

MalaCards integrated aliases for Epileptic Encephalopathy, Early Infantile, 2:

Name: Epileptic Encephalopathy, Early Infantile, 2 ⁵⁸ ⁷⁶ ¹³ ⁷⁴

Early Infantile Epileptic Encephalopathy 2 ¹² ³⁰ ⁶ ¹⁵

Eiee2 ⁵⁸ ⁷⁶

Issx2 ⁵⁸ ⁷⁶

Infantile Spasm Syndrome, X-Linked 2; Issx2 ⁵⁸

Rett Syndrome Variant with Infantile Spasms ⁷⁶

Rett Syndrome Early-Onset Seizure Variant ⁷⁶

Atypical Rett Syndrome Hanefeld Variant ⁷⁶

Cdkl5-Related Epileptic Encephalopathy ⁶⁰

Infantile Spasm Syndrome, X-Linked 2 ⁵⁸

Atypical Rett Syndrome Cdkl5-Related ⁷⁶

X-Linked Infantile Spasm Syndrome 2 ¹²

Infantile Spasm Syndrome X-Linked 2 ⁷⁶

Cdkl5 Deficiency Disorder ⁶⁰

Characteristics:

OMIM:

⁵⁸

Miscellaneous:
onset in infancy
males are more severely affected
seizures are usually refractory
females are most often affected, but rare male cases have been reported
dysmorphic facial features are subtle
some phenotypic overlap with rett syndrome

Inheritance:
x-linked dominant

HPO:

³³

epileptic encephalopathy, early infantile, 2:
Onset and clinical course infantile onset
Inheritance x-linked dominant inheritance

Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases Metabolic diseases Fetal diseases
Anatomical: Neuronal diseases Mental diseases Liver diseases Eye diseases

See all MalaCards categories (disease lists)

Orphanet: ⁶⁰

Rare neurological diseases

External Ids:

Disease Ontology ¹² DOID:0080467

OMIM ⁵⁸ 300672

MeSH ⁴⁵ D013036

Orphanet ⁶⁰ ORPHA505652

MedGen ⁴³ C1839333

SNOMED-CT via HPO ⁷⁰ 111266001 127324008 128613002 more

UMLS ⁷⁴ C1839333

Sources

Summaries for Epileptic Encephalopathy, Early Infantile, 2

OMIM : ⁵⁸ Early infantile epileptic encephalopathy-2 is an X-linked dominant severe neurologic disorder characterized by onset of seizures in the first months of life and severe global developmental delay resulting in mental retardation and poor motor control. Other features include lack of speech development, subtle dysmorphic facial features, sleep disturbances, gastrointestinal problems, and stereotypic hand movements. There is some phenotypic overlap with Rett syndrome (312750), but EIEE2 is considered to be a distinct entity (summary by Fehr et al., 2013). For a general phenotypic description and a discussion of genetic heterogeneity of EIEE, see EIEE1 (308350). (300672)

MalaCards based summary : Epileptic Encephalopathy, Early Infantile, 2, also known as early infantile epileptic encephalopathy 2, is related to rett syndrome and cdkl5 deficiency disorder, and has symptoms including constipation, myoclonus and difficulty sleeping. An important gene associated with Epileptic Encephalopathy, Early Infantile, 2 is CDKL5 (Cyclin Dependent Kinase Like 5). The drugs Ethanol and Strawberry have been mentioned in the context of this disorder. Affiliated tissues include eye, and related phenotypes are eeg with generalized slow activity and seizures

Disease Ontology : ¹² An early infantile epileptic encephalopathy characterized by X-linked dominant inheritance of seizure onset in the first months of life, intellectual disability, and poor motor control that has material basis in mutation in the CDKL5 gene on chromosome Xp22.

UniProtKB/Swiss-Prot : ⁷⁶ Epileptic encephalopathy, early infantile, 2: A severe form of epilepsy characterized by seizures or spasms beginning in infancy. Patients with epileptic encephalopathy early infantile type 2 manifest features resembling Rett syndrome such as microcephaly, lack of speech development, stereotypic hand movements. However, EIEE2 and Rett syndrome are considered two distinct entities.

Sources

Related Diseases for Epileptic Encephalopathy, Early Infantile, 2

Diseases in the Early Infantile Epileptic Encephalopathy family:

Diseases related to Epileptic Encephalopathy, Early Infantile, 2 via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 15)

#	Related Disease	Score	Top Affiliating Genes
1	rett syndrome	29.5	CDKL5 MECP2
2	cdkl5 deficiency disorder	11.4
3	epilepsy	10.2
4	gait apraxia	9.8	CDKL5 MECP2
5	bruxism	9.8	CDKL5 MECP2
6	epileptic encephalopathy, early infantile, 9	9.8	CDKL5 MECP2
7	encephalopathy	9.8	CDKL5 MECP2
8	brain cancer	9.8	NOTCH1 USP9X
9	seizure disorder	9.8	CDKL5 MECP2
10	specific developmental disorder	9.8	CDKL5 MECP2
11	pervasive developmental disorder	9.7	CDKL5 MECP2
12	x-linked non-specific intellectual disability	9.7	MECP2 USP9X
13	visual epilepsy	9.7	CDKL5 MECP2
14	angelman syndrome	9.7	CDKL5 MECP2
15	west syndrome	9.6	CDKL5 MECP2

Graphical network of the top 20 diseases related to Epileptic Encephalopathy, Early Infantile, 2:

Sources

Symptoms & Phenotypes for Epileptic Encephalopathy, Early Infantile, 2

Human phenotypes related to Epileptic Encephalopathy, Early Infantile, 2:

³³ (show all 31)

#	Description	HPO Frequency	HPO Source Accession
1	eeg with generalized slow activity ³³	very rare (1%)	HP:0010845
2	seizures ³³		HP:0001250
3	muscular hypotonia ³³		HP:0001252
4	constipation ³³		HP:0002019
5	developmental regression ³³		HP:0002376
6	scoliosis ³³		HP:0002650
7	global developmental delay ³³		HP:0001263
8	anteverted nares ³³		HP:0000463
9	gastroesophageal reflux ³³		HP:0002020
10	stereotypy ³³		HP:0000733
11	prominent forehead ³³		HP:0011220
12	generalized myoclonic seizures ³³		HP:0002123
13	thick lower lip vermilion ³³		HP:0000179
14	short palm ³³		HP:0004279
15	short foot ³³		HP:0001773
16	myoclonus ³³		HP:0001336
17	inability to walk ³³		HP:0002540
18	broad forehead ³³		HP:0000337
19	deeply set eye ³³		HP:0000490
20	small hand ³³		HP:0200055
21	intellectual disability, profound ³³		HP:0002187
22	infantile spasms ³³		HP:0012469
23	tapered finger ³³		HP:0001182
24	generalized hypotonia ³³		HP:0001290
25	hypsarrhythmia ³³		HP:0002521
26	epileptic encephalopathy ³³		HP:0200134
27	progressive microcephaly ³³		HP:0000253
28	hyperventilation ³³		HP:0002883
29	poor eye contact ³³		HP:0000817
30	multifocal seizures ³³		HP:0031165
31	cerebral visual impairment ³³		HP:0100704

Symptoms via clinical synopsis from OMIM:

⁵⁸

Abdomen Gastrointestinal:
constipation
gastroesophageal reflux

Head And Neck Nose:
anteverted nares

Neurologic Central Nervous System:
myoclonus
generalized seizures
infantile spasms
hypsarrhythmia
poor eye contact
more

Muscle Soft Tissue:
hypotonia

Neurologic Behavioral Psychiatric Manifestations:
autistic features
breath-holding episodes
stereotyped behaviors
hand-wringing

Head And Neck Mouth:
full lips

Head And Neck Head:
microcephaly, progressive

Skeletal Spine:
scoliosis

Head And Neck Face:
prominent forehead
broad forehead

Respiratory:
hyperventilation
breath-holding episodes

Head And Neck Eyes:
well-defined eyebrows
deep-set eyes
large-appearing eyes

Skeletal Hands:
small hands
tapering fingers

Skeletal Feet:
small feet

Clinical features from OMIM:

300672

UMLS symptoms related to Epileptic Encephalopathy, Early Infantile, 2:

constipation, myoclonus, difficulty sleeping, myoclonic seizures

GenomeRNAi Phenotypes related to Epileptic Encephalopathy, Early Infantile, 2 according to GeneCards Suite gene sharing:

²⁷ (show all 15)

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Increased shRNA abundance (Z-score > 2)	GR00366-A-107	9.83	USP9X
2	Increased shRNA abundance (Z-score > 2)	GR00366-A-120	9.83	NOTCH1
3	Increased shRNA abundance (Z-score > 2)	GR00366-A-130	9.83	USP9X
4	Increased shRNA abundance (Z-score > 2)	GR00366-A-138	9.83	NOTCH1 USP9X
5	Increased shRNA abundance (Z-score > 2)	GR00366-A-147	9.83	NOTCH1
6	Increased shRNA abundance (Z-score > 2)	GR00366-A-161	9.83	NOTCH1
7	Increased shRNA abundance (Z-score > 2)	GR00366-A-205	9.83	NOTCH1
8	Increased shRNA abundance (Z-score > 2)	GR00366-A-214	9.83	NOTCH1
9	Increased shRNA abundance (Z-score > 2)	GR00366-A-29	9.83	USP9X
10	Increased shRNA abundance (Z-score > 2)	GR00366-A-6	9.83	NOTCH1
11	Increased shRNA abundance (Z-score > 2)	GR00366-A-65	9.83	NOTCH1
12	Increased shRNA abundance (Z-score > 2)	GR00366-A-67	9.83	USP9X
13	Increased shRNA abundance (Z-score > 2)	GR00366-A-73	9.83	NOTCH1
14	Increased shRNA abundance (Z-score > 2)	GR00366-A-88	9.83	USP9X
15	shRNA abundance <= 50%	GR00343-S	8.92	CDKL5 MECP2 NOTCH1 USP9X

MGI Mouse Phenotypes related to Epileptic Encephalopathy, Early Infantile, 2:

⁴⁷

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	nervous system	MP:0003631	9.26	CDKL5 MECP2 NOTCH1 USP9X
2	no phenotypic analysis	MP:0003012	8.8	CDKL5 MECP2 USP9X

Sources

Drugs & Therapeutics for Epileptic Encephalopathy, Early Infantile, 2

Drugs for Epileptic Encephalopathy, Early Infantile, 2 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 34)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Ethanol

Approved

Phase 3,Phase 2

64-17-5

702

Strawberry

Approved

Phase 3,Phase 2

Stiripentol

Approved

Phase 3

49763-96-4

tannic acid

Approved

Phase 3,Phase 2

1401-55-4

Benzocaine

Approved, Investigational

Phase 3,Phase 2

94-09-7, 1994-09-7

2337

Clobazam

Approved, Illicit

Phase 3

22316-47-8

2789

Epidiolex

Phase 3,Phase 2,Phase 1

Anticonvulsants

Phase 3,Phase 2,Phase 1

Pharmaceutical Solutions

Phase 3,Phase 2,Phase 1

Serotonin Agents

Phase 3,Phase 1,Phase 2

Serotonin Uptake Inhibitors

Phase 3,Phase 1,Phase 2

Neurotransmitter Agents

Phase 3,Phase 1,Phase 2

Neurotransmitter Uptake Inhibitors

Phase 3,Phase 1,Phase 2

Central Nervous System Depressants

Phase 3

Pregnanolone

Phase 3

128-20-1

Anesthetics

Phase 3

Anti-Anxiety Agents

Phase 3

GABA Agents

Phase 3

Tranquilizing Agents

Phase 3

GABA Agonists

Phase 3

GABA-A Receptor Agonists

Phase 3

Psychotropic Drugs

Phase 3

Serotonin

Investigational, Nutraceutical

Phase 3,Phase 1,Phase 2

50-67-9

5202

Verapamil

Approved

Phase 2

52-53-9

2520

Calcium

Approved, Nutraceutical

Phase 2

7440-70-2

271

Calcium, Dietary

Phase 2

Vasodilator Agents

Phase 2

calcium channel blockers

Phase 2

Anti-Arrhythmia Agents

Phase 2

Hormones

Phase 2

Dronabinol

Approved, Illicit

Phase 1

1972-08-3

16078

Racepinephrine

Approved

329-65-7

838

Epinephrine

Approved, Vet_approved

51-43-4

5816

Epinephryl borate

Interventional clinical trials:

(show all 39)

#	Name	Status	NCT ID	Phase	Drugs
1	GWPCARE2 A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome	Unknown status	NCT02224703	Phase 3	GWP42003-P;Placebo Control
2	A Two-Part Study to Investigate the Dose-Ranging Safety and Pharmacokinetics, Followed by the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy in Children ≥2 Years Old and Young Adults With Dravet Syndrome	Completed	NCT02926898	Phase 3	ZX008 - 0.2 mg/kg/day;ZX008 - 0.4 mg/kg/day;ZX008 - 20 mg/day maximum dose;Matching Placebo
3	Antiepileptic Efficacy Study of GWP42003-P in Children and Young Adults With Dravet Syndrome (GWPCARE1)	Completed	NCT02091375	Phase 3	GWP42003-P 20 mg/kg/day Dose;Placebo control
4	Cannabidiol Oral Solution as an Adjunctive Treatment for Treatment-resistant Seizure Disorder	Completed	NCT02318602	Phase 3	Cannabidiol Oral Solution
5	A Trial of Two Fixed Doses of ZX008 (Fenfluramine HCl) as an Adjunctive Therapy in Children and Young Adults With Dravet Syndrome	Recruiting	NCT02826863	Phase 3	ZX008 - 0.8 mg/kg/day;ZX008 - 0.2 mg/kg/day;Placebo
6	Study of Adjunctive Ganaxolone Treatment in Children and Young Adults With CDKL5 Deficiency Disorder	Recruiting	NCT03572933	Phase 3	ganaxolone;Placebo
7	A Trial of Two Fixed Doses of ZX008 (Fenfluramine HCl) in Children and Young Adults With Dravet Syndrome	Active, not recruiting	NCT02682927	Phase 3	ZX008 (Fenfluramine Hydrochloride);Matching Placebo
8	A Study to Assess the Usability of the Embrace Seizure Detection Watch in Children and Young Adults With Dravet Syndrome	Enrolling by invitation	NCT03299842	Phase 3	ZX008 (Fenfluramine Hydrochloride)
9	An Open-Label Extension Trial to Assess the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride HCl) Oral Solution in Children and Young Adults With Dravet Syndrome	Enrolling by invitation	NCT02823145	Phase 3	ZX008 (Fenfluramine Hydrochloride)
10	GWPCARE5 - An Open Label Extension Study of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet or Lennox-Gastaut Syndromes	Enrolling by invitation	NCT02224573	Phase 3	GWP42003-P
11	Safety and Tolerability of Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet Syndrome	Terminated	NCT02187809	Phase 3	Clobazam
12	Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet Syndrome	Withdrawn	NCT02174094	Phase 3	Clobazam;Placebo
13	Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Dravet Syndrome	Withdrawn	NCT02318563	Phase 3	Cannabidiol Oral Solution;Placebo Solution
14	Verapamil as Therapy for Children and Young Adults With Dravet Syndrome	Completed	NCT01607073	Phase 2	Verapamil
15	A Dose-ranging Pharmacokinetics and Safety Study of GWP42003-P in Children With Dravet Syndrome (GWPCARE1)	Completed	NCT02091206	Phase 2	GWP42003-P 5 mg/kg/day Dose;Placebo control;GWP42003-P 10 mg/kg/day Dose;GWP42003-P 20 mg/kg/day Dose
16	A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Patients With Developmental and/or Epileptic Encephalopathies	Recruiting	NCT03650452	Phase 2	TAK-935;Placebo
17	A Phase 2, Prospective, Interventional, Open-Label, Multi-Site, Extension Study to Assess the Long-Term Safety and Tolerability of TAK-935 (OV935) as Adjunctive Therapy in Patients With Rare Epilepsy	Recruiting	NCT03635073	Phase 2	TAK-935
18	A Multicenter, Open-label, Pilot Study of TAK-935 (OV935) in Participants With 15Q Duplication Syndrome or Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder (ARCADE STUDY)	Recruiting	NCT03694275	Phase 2	TAK-935
19	Ataluren for Nonsense Mutation in CDKL5 and Dravet Syndrome	Active, not recruiting	NCT02758626	Phase 2	ataluren;Placebo
20	A Study to Assess the Safety and Tolerability of ZX008 in Children and Young Adults With DS or LGS Currently Taking CBD	Active, not recruiting	NCT03467113	Phase 1, Phase 2	ZX008 02 and 0.8 mg/kg/day
21	Fenfluramine in CDD	Not yet recruiting	NCT03861871	Phase 2	Fenfluramine Hydrochloride
22	The Effects of Cannabidiol (CBD) on Electrical and Autonomic Cardiac Function in Children With Severe Epilepsy	Terminated	NCT02815540	Phase 1, Phase 2	Cannabidiol
23	Cannabidiol in Children With Refractory Epileptic Encephalopathy	Recruiting	NCT03024827	Phase 1	CanniMed® 1:20
24	Cannabinoid Therapy for Pediatric Epilepsy	Active, not recruiting	NCT02983695	Phase 1	TIL-TC150
25	Cannabidiol (CBD) to 27 Patients (Aged 2 Years - 19 Years) With Drug Resistant Epilepsy	Active, not recruiting	NCT02286986	Phase 1	Cannabidiol
26	Cardiac Arrhythmias in Dravet Syndrome	Completed	NCT02415686
27	Genetic Analysis Between Charlotte's Web Responders Versus Non- Responders in a Dravet Population	Completed	NCT02229032
28	Treatment of Gait Disorders in Children With Dravet Syndrome	Recruiting	NCT03857451
29	Neuronal Excitability of HCN1 Channel Mutations in Dravet Syndrome	Recruiting	NCT02896608
30	Risk Factors for Sudden Unexplained Death in Epilepsy	Recruiting	NCT01662453
31	Genetics of Severe Early Onset Epilepsies	Recruiting	NCT01858285
32	Treatment Plan to Provide Expanded Access to Stiripentol for Patients With Dravet Syndrome	Available	NCT01983722		Stiripentol
33	Compassionate Use of Stiripentol in Dravet Syndrome	Available	NCT01835314		Stiripentol
34	ZX008 Expanded Access Protocol	Available	NCT03780127		Fenfluramine Hydrochloride
35	Multi-center Clinical Study on the Diagnosis and Treatment Management of Rare Neurological Disease in Children	Not yet recruiting	NCT03649919
36	Stiripentol in Dravet Syndrome	No longer available	NCT01533506		stiripentol
37	Expanded Access Use of Stiripentol in Dravet Syndrome or Sodium Channel Mutation Epileptic Encephalopathies	No longer available	NCT02239276		Stiripentol
38	The Pharmacokinetics of Cannabidiol (CBD) and Its Effects in Children With Severe Epilepsy	Withdrawn	NCT02910297
39	Turmeric as Treatment in Epilepsy	Withdrawn	NCT03254680	Not Applicable

Search NIH Clinical Center for Epileptic Encephalopathy, Early Infantile, 2

Sources

Genetic Tests for Epileptic Encephalopathy, Early Infantile, 2

Genetic tests related to Epileptic Encephalopathy, Early Infantile, 2:

#	Genetic test	Affiliating Genes
1	Early Infantile Epileptic Encephalopathy 2 ³⁰	CDKL5

Sources

Anatomical Context for Epileptic Encephalopathy, Early Infantile, 2

MalaCards organs/tissues related to Epileptic Encephalopathy, Early Infantile, 2:

⁴²

Eye

Sources

Publications for Epileptic Encephalopathy, Early Infantile, 2

Articles related to Epileptic Encephalopathy, Early Infantile, 2:

#	Title	Authors	Year
1	CDKL5/STK9 is mutated in Rett syndrome variant with infantile spasms. ( 15689447 )	Scala E....Renieri A.	2005

Sources

Genes for Epileptic Encephalopathy, Early Infantile, 2

Genes related to Epileptic Encephalopathy, Early Infantile, 2 (1 elite genes):

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	CDKL5	Cyclin Dependent Kinase Like 5	Protein Coding	1686.67	Molecular basis known ⁵⁸ Pathogenic ⁶ Causative germline mutation ⁶⁰ Causative variation ⁷⁶ Genetic Tests ³⁰ DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Variants (show sections)	15492925 15689447 16611748 (more) 19241098 15499549 16813600 19396824 18809835 19793311 17993579
2	USP9X	Ubiquitin Specific Peptidase 9 X-Linked	Protein Coding	16.04	DISEASES inferred ¹⁵
3	MECP2	Methyl-CpG Binding Protein 2	Protein Coding	14.72	DISEASES inferred ¹⁵
4	NOTCH1	Notch Receptor 1	Protein Coding	13.83	DISEASES inferred ¹⁵

Sources

Variations for Epileptic Encephalopathy, Early Infantile, 2

UniProtKB/Swiss-Prot genetic disease variations for Epileptic Encephalopathy, Early Infantile, 2:

⁷⁶ (show all 18)

#	Symbol	AA change	Variation ID	SNP ID
1	CDKL5	p.Cys152Phe	VAR_023560	rs122460157
2	CDKL5	p.Arg175Ser	VAR_023561	rs61749700
3	CDKL5	p.Pro180Leu	VAR_037635	rs61749704
4	CDKL5	p.Ala40Val	VAR_058022	rs122460159
5	CDKL5	p.Ile72Asn	VAR_058023	rs62641235
6	CDKL5	p.Ile72Thr	VAR_058024	rs62641235
7	CDKL5	p.His127Arg	VAR_058025	rs267608468
8	CDKL5	p.Arg178Pro	VAR_058026	rs267606715
9	CDKL5	p.Leu220Pro	VAR_058027	rs267608511
10	CDKL5	p.Thr288Ile	VAR_058028	rs267606713
11	CDKL5	p.Cys291Tyr	VAR_058029	rs267606714
12	CDKL5	p.Asn399Thr	VAR_058030	rs267608611
13	CDKL5	p.Val718Met	VAR_058032	rs267608653
14	CDKL5	p.Arg178Gln	VAR_071103	rs267606715
15	CDKL5	p.Ser196Leu	VAR_078219	rs267608501
16	CDKL5	p.Leu182Pro	VAR_078626
17	CDKL5	p.Gly207Glu	VAR_078627
18	CDKL5	p.Arg178Trp	VAR_078712	rs267608493

ClinVar genetic disease variations for Epileptic Encephalopathy, Early Infantile, 2:

⁶ (show top 50) (show all 414)

#	Gene	Variation	Type	Significance	SNP ID	Assembly	Location
1	CDKL5	NM_003159.2(CDKL5): c.62A> G (p.Glu21Gly)	single nucleotide variant	Likely pathogenic	rs587783406	GRCh37	Chromosome X, 18525278: 18525278
2	CDKL5	NM_003159.2(CDKL5): c.62A> G (p.Glu21Gly)	single nucleotide variant	Likely pathogenic	rs587783406	GRCh38	Chromosome X, 18507158: 18507158
3	CDKL5	NM_003159.2(CDKL5): c.146-1G> A	single nucleotide variant	Pathogenic	rs587783399	GRCh37	Chromosome X, 18593473: 18593473
4	CDKL5	NM_003159.2(CDKL5): c.146-1G> A	single nucleotide variant	Pathogenic	rs587783399	GRCh38	Chromosome X, 18575353: 18575353
5	CDKL5	NM_003159.2(CDKL5): c.248G> T (p.Gly83Val)	single nucleotide variant	Uncertain significance	rs587783402	GRCh37	Chromosome X, 18593576: 18593576
6	CDKL5	NM_003159.2(CDKL5): c.248G> T (p.Gly83Val)	single nucleotide variant	Uncertain significance	rs587783402	GRCh38	Chromosome X, 18575456: 18575456
7	CDKL5	NM_003159.2(CDKL5): c.283-13A> G	single nucleotide variant	Conflicting interpretations of pathogenicity	rs587783404	GRCh37	Chromosome X, 18597955: 18597955
8	CDKL5	NM_003159.2(CDKL5): c.283-13A> G	single nucleotide variant	Conflicting interpretations of pathogenicity	rs587783404	GRCh38	Chromosome X, 18579835: 18579835
9	CDKL5	NM_003159.2(CDKL5): c.526T> C (p.Trp176Arg)	single nucleotide variant	Likely pathogenic	rs587783084	GRCh37	Chromosome X, 18602445: 18602445
10	CDKL5	NM_003159.2(CDKL5): c.526T> C (p.Trp176Arg)	single nucleotide variant	Likely pathogenic	rs587783084	GRCh38	Chromosome X, 18584325: 18584325
11	CDKL5	NM_003159.2(CDKL5): c.622C> T (p.Gln208Ter)	single nucleotide variant	Pathogenic	rs587783405	GRCh37	Chromosome X, 18606141: 18606141
12	CDKL5	NM_003159.2(CDKL5): c.622C> T (p.Gln208Ter)	single nucleotide variant	Pathogenic	rs587783405	GRCh38	Chromosome X, 18588021: 18588021
13	CDKL5	NM_003159.2(CDKL5): c.969G> A (p.Leu323=)	single nucleotide variant	Uncertain significance	rs587783407	GRCh37	Chromosome X, 18616725: 18616725
14	CDKL5	NM_003159.2(CDKL5): c.969G> A (p.Leu323=)	single nucleotide variant	Uncertain significance	rs587783407	GRCh38	Chromosome X, 18598605: 18598605
15	CDKL5	NM_003159.2(CDKL5): c.1345_1346del (p.Glu449Lysfs)	deletion	Pathogenic	rs587783398	GRCh37	Chromosome X, 18622389: 18622390
16	CDKL5	NM_003159.2(CDKL5): c.1345_1346del (p.Glu449Lysfs)	deletion	Pathogenic	rs587783398	GRCh38	Chromosome X, 18604269: 18604270
17	CDKL5	NM_003159.2(CDKL5): c.1678A> G (p.Thr560Ala)	single nucleotide variant	Uncertain significance	rs587783400	GRCh37	Chromosome X, 18622722: 18622722
18	CDKL5	NM_003159.2(CDKL5): c.1678A> G (p.Thr560Ala)	single nucleotide variant	Uncertain significance	rs587783400	GRCh38	Chromosome X, 18604602: 18604602
19	CDKL5	NM_003159.2(CDKL5): c.1797dup (p.Ser600Glnfs)	duplication	Pathogenic	rs587783401	GRCh37	Chromosome X, 18622841: 18622841
20	CDKL5	NM_003159.2(CDKL5): c.1797dup (p.Ser600Glnfs)	duplication	Pathogenic	rs587783401	GRCh38	Chromosome X, 18604721: 18604721
21	CDKL5	NM_003159.2(CDKL5): c.2820C> A (p.Asp940Glu)	single nucleotide variant	Uncertain significance	rs587783403	GRCh37	Chromosome X, 18668552: 18668552
22	CDKL5	NM_003159.2(CDKL5): c.2820C> A (p.Asp940Glu)	single nucleotide variant	Uncertain significance	rs587783403	GRCh38	Chromosome X, 18650432: 18650432
23	CDKL5	NM_003159.2(CDKL5): c.-253_-163+?del	deletion	Likely pathogenic		GRCh37	Chromosome X, 18443725: 18443815
24	CDKL5	NM_003159.2(CDKL5): c.-253_-163+?del	deletion	Likely pathogenic		GRCh38	Chromosome X, 18425605: 18425695
25	CDKL5	NM_003159.2(CDKL5): c.-253_99+?del	deletion	Pathogenic		GRCh37	Chromosome X, 18443725: 18528974
26	CDKL5	NM_003159.2(CDKL5): c.-253_99+?del	deletion	Pathogenic		GRCh38	Chromosome X, 18425605: 18510854
27	CDKL5	NM_003159.2(CDKL5): c.-253_825+?del	deletion	Pathogenic		GRCh37	Chromosome X, 18443725: 18613548
28	CDKL5	NM_003159.2(CDKL5): c.-253_825+?del	deletion	Pathogenic		GRCh38	Chromosome X, 18425605: 18595428
29	CDKL5	NM_003159.2(CDKL5): c.-253_977+?del	deletion	Pathogenic		GRCh37	Chromosome X, 18443725: 18616733
30	CDKL5	NM_003159.2(CDKL5): c.-253_977+?del	deletion	Pathogenic		GRCh38	Chromosome X, 18425605: 18598613
31	CDKL5	NM_003159.2(CDKL5): c.-253_2276+?del	deletion	Pathogenic		GRCh38	Chromosome X, 18425605: 18613275
32	CDKL5	NM_003159.2(CDKL5): c.-253_2276+?del	deletion	Pathogenic		GRCh37	Chromosome X, 18443725: 18631395
33	CDKL5	NM_003159.2(CDKL5): c.-162-?_64+?del	deletion	Pathogenic
34	CDKL5	NM_003159.2(CDKL5): c.-162-?_99+?del	deletion	Pathogenic
35	CDKL5	NM_003159.2(CDKL5): c.-162-?_145+?del	deletion	Pathogenic
36	CDKL5	NM_003159.2(CDKL5): c.-162-?_*85del	deletion	Pathogenic		GRCh37	Chromosome X, 18525055: 18671749
37	CDKL5	NM_003159.2(CDKL5): c.-162-?_*85del	deletion	Pathogenic		GRCh38	Chromosome X, 18506935: 18653629
38	CDKL5	NM_003159.2(CDKL5): c.65-?_99+?del	deletion	Pathogenic
39	CDKL5	NM_003159.2(CDKL5): c.100-?_145+?del	deletion	Pathogenic
40	CDKL5	NM_003159.2(CDKL5): c.146-?_*85del	deletion	Pathogenic		GRCh37	Chromosome X, 18593474: 18671749
41	CDKL5	NM_003159.2(CDKL5): c.146-?_*85del	deletion	Pathogenic		GRCh38	Chromosome X, 18575354: 18653629
42	CDKL5	NM_003159.2(CDKL5): c.745-?_825+?del	deletion	Pathogenic
43	CDKL5	NM_003159.2(CDKL5): c.2377-?_*85del	deletion	Pathogenic		GRCh37	Chromosome X, 18643248: 18671749
44	CDKL5	NM_003159.2(CDKL5): c.2377-?_*85del	deletion	Pathogenic		GRCh38	Chromosome X, 18625128: 18653629
45	CDKL5	NM_003159.2(CDKL5): c.2497-?_*85del	deletion	Pathogenic		GRCh38	Chromosome X, 18628371: 18653629
46	CDKL5	NM_003159.2(CDKL5): c.2497-?_*85del	deletion	Pathogenic		GRCh37	Chromosome X, 18646491: 18671749
47	CDKL5	NM_003159.2(CDKL5): c.-162-2A> G	single nucleotide variant	Pathogenic	rs786204973	GRCh38	Chromosome X, 18506933: 18506933
48	CDKL5	NM_003159.2(CDKL5): c.-162-2A> G	single nucleotide variant	Pathogenic	rs786204973	GRCh37	Chromosome X, 18525053: 18525053
49	CDKL5	NM_003159.2(CDKL5): c.91A> G (p.Arg31Gly)	single nucleotide variant	Pathogenic	rs786204991	GRCh37	Chromosome X, 18528966: 18528966
50	CDKL5	NM_003159.2(CDKL5): c.91A> G (p.Arg31Gly)	single nucleotide variant	Pathogenic	rs786204991	GRCh38	Chromosome X, 18510846: 18510846

Sources

Expression for Epileptic Encephalopathy, Early Infantile, 2

Search GEO for disease gene expression data for Epileptic Encephalopathy, Early Infantile, 2.

Sources

Pathways for Epileptic Encephalopathy, Early Infantile, 2

Sources

GO Terms for Epileptic Encephalopathy, Early Infantile, 2

Biological processes related to Epileptic Encephalopathy, Early Infantile, 2 according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	negative regulation of gene expression	GO:0010629	9.37	MECP2 NOTCH1
2	brain development	GO:0007420	9.32	MECP2 NOTCH1
3	regulation of gene expression	GO:0010468	9.26	MECP2 NOTCH1
4	neuron differentiation	GO:0030182	9.16	MECP2 NOTCH1
5	negative regulation of transcription by RNA polymerase II	GO:0000122	9.13	MECP2 NOTCH1 USP9X
6	neuron migration	GO:0001764	8.62	CDKL5 USP9X

Sources

Sources for Epileptic Encephalopathy, Early Infantile, 2

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FDA Approved Drugs

²⁰ FMA

²¹ GeneAnalytics

²² GeneCards

²³ GeneGo (Thomson Reuters)

²⁴ GeneHancer via GeneCards

²⁵ GeneReviews

²⁶ Genetics Home Reference

²⁷ GenomeRNAi

²⁸ GEO DataSets

²⁹ GO

³⁰ GTR

³¹ HGMD

³² HMDB

³³ HPO

³⁴ ICD10

³⁵ ICD10 via Orphanet

³⁶ ICD9CM

³⁷ IUPHAR

³⁸ KEGG

³⁹ LifeMap

⁴⁰ LncRNADisease

⁴¹ LOVD

⁴² MalaCards

⁴³ MedGen

⁴⁴ MedlinePlus

⁴⁵ MeSH

⁴⁶ MESH via Orphanet

⁴⁷ MGI

⁴⁸ miR2Disease

⁴⁹ NCBI Bookshelf

⁵⁰ NCI

⁵¹ NCIt

⁵² NDF-RT

⁵³ NIH Clinical Center

⁵⁴ NIH Rare Diseases

⁵⁵ NINDS

⁵⁶ Novoseek

⁵⁷ Novus Biologicals

⁵⁸ OMIM

⁵⁹ OMIM via Orphanet

⁶⁰ Orphanet

⁶¹ PathCards

⁶² PharmGKB

⁶³ PubMed

⁶⁴ PubMed Health

⁶⁵ QIAGEN

⁶⁶ R&D Systems

⁶⁷ Reactome

⁶⁸ Sino Biological

⁶⁹ SNOMED-CT

⁷⁰ SNOMED-CT via HPO

⁷¹ SNOMED-CT via Orphanet

⁷² TGDB

⁷³ Tocris

⁷⁴ UMLS

⁷⁵ UMLS via Orphanet

⁷⁶ UniProtKB/Swiss-Prot

⁷⁷ Wikipedia

Epileptic Encephalopathy, Early Infantile, 2 (EIEE2)

Aliases & Classifications for Epileptic Encephalopathy, Early Infantile, 2

MalaCards integrated aliases for Epileptic Encephalopathy, Early Infantile, 2:

Characteristics:

OMIM:

HPO:

Classifications:

External Ids:

Summaries for Epileptic Encephalopathy, Early Infantile, 2

Related Diseases for Epileptic Encephalopathy, Early Infantile, 2

Diseases in the Early Infantile Epileptic Encephalopathy family:

Diseases related to Epileptic Encephalopathy, Early Infantile, 2 via text searches within MalaCards or GeneCards Suite gene sharing:

Graphical network of the top 20 diseases related to Epileptic Encephalopathy, Early Infantile, 2:

Symptoms & Phenotypes for Epileptic Encephalopathy, Early Infantile, 2

Human phenotypes related to Epileptic Encephalopathy, Early Infantile, 2:

Symptoms via clinical synopsis from OMIM:

Clinical features from OMIM:

UMLS symptoms related to Epileptic Encephalopathy, Early Infantile, 2:

GenomeRNAi Phenotypes related to Epileptic Encephalopathy, Early Infantile, 2 according to GeneCards Suite gene sharing:

MGI Mouse Phenotypes related to Epileptic Encephalopathy, Early Infantile, 2:

Drugs & Therapeutics for Epileptic Encephalopathy, Early Infantile, 2

Drugs for Epileptic Encephalopathy, Early Infantile, 2 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

Interventional clinical trials:

Genetic Tests for Epileptic Encephalopathy, Early Infantile, 2

Genetic tests related to Epileptic Encephalopathy, Early Infantile, 2:

Anatomical Context for Epileptic Encephalopathy, Early Infantile, 2

MalaCards organs/tissues related to Epileptic Encephalopathy, Early Infantile, 2:

Publications for Epileptic Encephalopathy, Early Infantile, 2

Articles related to Epileptic Encephalopathy, Early Infantile, 2:

Genes for Epileptic Encephalopathy, Early Infantile, 2

Genes related to Epileptic Encephalopathy, Early Infantile, 2 (1 elite genes):

Variations for Epileptic Encephalopathy, Early Infantile, 2

UniProtKB/Swiss-Prot genetic disease variations for Epileptic Encephalopathy, Early Infantile, 2:

ClinVar genetic disease variations for Epileptic Encephalopathy, Early Infantile, 2:

Expression for Epileptic Encephalopathy, Early Infantile, 2

Pathways for Epileptic Encephalopathy, Early Infantile, 2

GO Terms for Epileptic Encephalopathy, Early Infantile, 2

Biological processes related to Epileptic Encephalopathy, Early Infantile, 2 according to GeneCards Suite gene sharing:

Sources for Epileptic Encephalopathy, Early Infantile, 2